Peptide hormones http://www.globalpost.com/taxonomy/term/29024/all en Denmark faces Nokia moment as Novo weighs in at $100 bln http://www.globalpost.com/dispatch/news/thomson-reuters/130201/denmark-faces-nokia-moment-novo-weighs-at-100-bln <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>* Novo Nordisk biggest firm by market cap in the Nordics</p> <p>* Shares up almost 40 pct in 2012 on strong global insulin demand</p> <p>* Stock exchange changing key index to cap weighting at 20 pct</p> <p>By Mia Shanley and Shida Chayesteh</p> <p>COPENHAGEN, Feb 1 (Reuters) - Denmark is facing its "Nokia moment"; drugmaker Novo Nordisk has ballooned into a $100 billion giant, dominating its home stock market just as the Finnish firm did at the height of the 1990s tech boom.</p> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130201/denmark-faces-nokia-moment-novo-weighs-at-100-bln" target="_blank">read more</a></p> Biology Business Disaster Human Interest Labor Law Novo Nordisk Novo Nordisk Peptide hormones Technology Thomson Reuters Fri, 01 Feb 2013 08:30:39 +0000 5742662 at http://www.globalpost.com URGENT ¥¥¥ Novo Nordisk share plunges on insulin setback http://www.globalpost.com/dispatch/news/afp/130211/urgent-novo-nordisk-share-plunges-insulin-setback <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Shares in the world's biggest insulin producer Novo Nordisk plunged by 13 percent on Monday after the company said US drug authorities had rejected its applications for two new insulin treatments.</p> <p>The Danish company said it had received a letter from the US Food and Drug Administration stating "that approvals for Tresiba and Ryzodeg cannot be granted" until the company provides additional information.</p> <p>po/nsb/hd</p> Biology Peptide hormones Recombinant proteins AFP Mon, 11 Feb 2013 09:16:25 +0000 5752414 at http://www.globalpost.com Novo Nordisk shares plunges on insulin setback http://www.globalpost.com/dispatch/news/afp/130211/novo-nordisk-shares-plunges-insulin-setback <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Shares in the world's biggest insulin producer Novo Nordisk plunged by up to 15 percent on Monday after the company said US drug authorities had rejected its applications for two new insulin treatments.</p> <p>The Danish company said it had received a letter from the US Food and Drug Administration (FDA) stating "that approvals for Tresiba and Ryzodeg cannot be granted" until the company provides additional information.</p> <p>The FDA requested more cardiovascular data, which Novo Nordisk said it was unlikely to be able to provide this year.</p> <p><a href="http://www.globalpost.com/dispatch/news/afp/130211/novo-nordisk-shares-plunges-insulin-setback" target="_blank">read more</a></p> Biology Peptide hormones Recombinant proteins AFP Mon, 11 Feb 2013 10:00:48 +0000 5752447 at http://www.globalpost.com Novo Nordisk shares plunge on insulin setback http://www.globalpost.com/dispatch/news/afp/130211/novo-nordisk-shares-plunge-insulin-setback <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>The world's biggest insulin producer Novo Nordisk Monday had 10.7 billion euros ($14.4 billion) wiped off its market value after the company said US authorities had rejected its applications for two new insulin treatments.</p> <p>Shares in the Danish company plunged by up to 15 percent after the US Food and Drug Administration (FDA) said "approvals for Tresiba and Ryzodeg cannot be granted" until the company provides additional information.</p> <p>The FDA requested more cardiovascular data, which Novo Nordisk said it was unlikely to be able to provide this year.</p> <p><a href="http://www.globalpost.com/dispatch/news/afp/130211/novo-nordisk-shares-plunge-insulin-setback" target="_blank">read more</a></p> Biology Peptide hormones Recombinant proteins AFP Mon, 11 Feb 2013 18:15:57 +0000 5752933 at http://www.globalpost.com Sanofi boosts Lantus insulin production in Ireland http://www.globalpost.com/dispatch/news/thomson-reuters/130213/sanofi-boosts-lantus-insulin-production-ireland <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>PARIS, Feb 13 (Reuters) - French drugmaker Sanofi said on Wednesday it would invest 44 million euros ($59 million) on its site in Waterford, Ireland, to boost production of its top-selling insulin, Lantus.</p> <p>The company, which has been reshuffling research and production sites in the United States and Europe after the patent loss of several key medicines, aims to start making Lantus at the site in 2016, Sanofi said in a statement.</p> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130213/sanofi-boosts-lantus-insulin-production-ireland" target="_blank">read more</a></p> Biology Peptide hormones Recombinant proteins Thomson Reuters Wed, 13 Feb 2013 15:48:21 +0000 5754639 at http://www.globalpost.com FDA staff say calcitonin salmon cancer risk appears plausible http://www.globalpost.com/dispatch/news/thomson-reuters/130301/fda-staff-say-calcitonin-salmon-cancer-risk-appears-plausible <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>March 1 (Reuters) - Staff reviewers for the U.S. Food and Drug Administration said that a potential increased risk of cancer with drugs containing calcitonin salmon appears plausible.</p> <p>In briefing documents released on Friday, the reviewers said the risk raises concerns about the overall risk versus benefit of calcitonin products to treat osteoporosis in postmenopausal women.</p> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130301/fda-staff-say-calcitonin-salmon-cancer-risk-appears-plausible" target="_blank">read more</a></p> Calcitonin Endocrine system Peptide hormones Thomson Reuters Fri, 01 Mar 2013 14:45:42 +0000 5770942 at http://www.globalpost.com FDA panel advises calcitonin salmon not be used for osteoporosis http://www.globalpost.com/dispatch/news/thomson-reuters/130305/fda-panel-advises-calcitonin-salmon-not-be-used-osteoporosis <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>March 5 (Reuters) - A panel of advisers to the U.S. Food and Drug Administration recommended on Tuesday that the agency no longer support the marketing of calcitonin salmon as a treatment for osteoporosis in post-menopausal women.</p> <p>The panel voted 12-9 that the benefit of calcitonin salmon products in treating bone-thinning associated with osteoporosis is outweighed by a potential increase in the risk of cancer.</p> <p>Calcitonin salmon is a man-made version of the hormone calcitonin that is found in salmon.</p> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130305/fda-panel-advises-calcitonin-salmon-not-be-used-osteoporosis" target="_blank">read more</a></p> Endocrine system Osteopathies Peptide hormones Thomson Reuters Wed, 06 Mar 2013 00:00:22 +0000 5774456 at http://www.globalpost.com Novo Nordisk posts better-than-expected earnings http://www.globalpost.com/dispatch/news/afp/130501/novo-nordisk-posts-better-expected-earnings <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Danish pharmaceutical group Novo Nordisk, the world's biggest producer of insulin for diabetes sufferers, on Wednesday topped analyst profit expectations for its first quarter of 2013</p> <p>From January to March, the group posted a net profit of 5.982 billion Danish kroner (802 million euros), as it enjoyed strong sales of its diabetic drug Victoza and "modern insulins."</p> <p>Analysts polled by Dow Jones Newswires predicted 5.85 billion kroner in net profit.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130501/novo-nordisk-posts-better-expected-earnings" target="_blank">read more</a></p> Diabetes Endocrine system Novo Nordisk Peptide hormones AFP Wed, 01 May 2013 07:45:20 +0000 5829074 at http://www.globalpost.com Danish drug maker Novo Nordisk Q1 net profits up 28 per cent on strong sales of diabetic drugs http://www.globalpost.com/dispatch/news/the-canadian-press/130501/danish-drug-maker-novo-nordisk-q1-net-profits-28-cent-strong <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> The Canadian Press </div> </div> </div> <!--paging_filter--><p>COPENHAGEN - Danish pharmaceutical company Novo Nordisk A/S says first-quarter net profit rose 28 per cent on strong sales of its diabetic drugs.</p> <p>The world's largest insulin maker said net profit in the first three months of 2013 was 5.9 million kroner ($1 million), up from 4.7 million kroner. Revenue for the period came in at 20 billion kroner ($3.5 billion), up 13 per cent.</p> <p><a href="http://www.globalpost.com/dispatch/news/the-canadian-press/130501/danish-drug-maker-novo-nordisk-q1-net-profits-28-cent-strong" target="_blank">read more</a></p> Biology Medicine Peptide hormones The Canadian Press Wed, 01 May 2013 08:15:39 +0000 5829083 at http://www.globalpost.com Novo obesity drug could launch in U.S. end 2014 http://www.globalpost.com/dispatch/news/thomson-reuters/130524/novo-obesity-drug-could-launch-us-end-2014 <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>COPENHAGEN (Reuters) - Danish drug maker Novo Nordisk said it could launch obesity treatment liraglutide in the United States by the end of next year and rejected some analysts' doubts over the medicine's commercial potential.</p> <p>The world's biggest insulin producer is hoping the treatment for severe obesity will help to at least partly offset the delay to its next generation insulin treatment Tresiba after U.S. regulators asked for more tests.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130524/novo-obesity-drug-could-launch-us-end-2014" target="_blank">read more</a></p> Endocrine system Health Labor Medicine Peptide hormones Social Issues Thomson Reuters Fri, 24 May 2013 11:36:14 +0000 5845414 at http://www.globalpost.com Novo Nordisk shares hit by concerns over rival diabetes drugs http://www.globalpost.com/dispatch/news/thomson-reuters/130617/novo-nordisk-shares-hit-concerns-over-rival-diabetes-drugs <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>By Mette Fraende</p> <p>COPENHAGEN (Reuters) - Novo Nordisk &lt;NOVOb.CO&gt;, the world's biggest insulin producer, faces more competition in the diabetes field from rivals Eli Lilly &lt;LLY.N&gt; and Sanofi &lt;SASY.PA&gt;, both of which will showcase new products at an upcoming medical meeting.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130617/novo-nordisk-shares-hit-concerns-over-rival-diabetes-drugs" target="_blank">read more</a></p> Anti-diabetic drugs Endocrine system Peptide hormones Thomson Reuters Mon, 17 Jun 2013 13:01:02 +0000 5858818 at http://www.globalpost.com Sanofi's next-generation insulin shows edge over Lantus http://www.globalpost.com/dispatch/news/thomson-reuters/130622/sanofis-next-generation-insulin-shows-edge-over-lantus <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>PARIS (Reuters) - An improved version of Sanofi's blockbuster insulin Lantus is better than the older drug at controlling blood sugar lows at night, a common side effect in diabetics treated with insulin, according two late-stage tests published on Saturday.</p> <p>The results for the next-generation treatment, known as U300, could strengthen Sanofi's position as it defends its no. 2 spot in the $43 billion diabetes market from rival drugs.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130622/sanofis-next-generation-insulin-shows-edge-over-lantus" target="_blank">read more</a></p> Biology Peptide hormones Recombinant proteins Sanofi Technology Thomson Reuters Sat, 22 Jun 2013 15:32:07 +0000 5864504 at http://www.globalpost.com Sanofi plans late-stage diabetes combo drug tests in 2014 http://www.globalpost.com/dispatch/news/thomson-reuters/130624/sanofi-plans-late-stage-diabetes-combo-drug-tests-2014 <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>PARIS (Reuters) - Sanofi aims to start late-stage tests for a pen device combining diabetes treatments Lantus and Lyxumia in the first half of 2014, according to slides posted on its website ahead of a presentation to investors on Monday.</p> <p>The French drugmaker said in May it was stepping up the development of the fixed-combination pen to sidestep an earlier setback with a similar device and take advantage of the delayed U.S. launch of competitor Novo Nordisk's new insulin.</p> <p>(Reporting by Elena Berton; Editing by James Regan)</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130624/sanofi-plans-late-stage-diabetes-combo-drug-tests-2014" target="_blank">read more</a></p> Biology Peptide hormones Recombinant proteins Technology Thomson Reuters Mon, 24 Jun 2013 13:02:30 +0000 5865700 at http://www.globalpost.com Sanofi wins diabetes drug approval in Japan http://www.globalpost.com/dispatch/news/thomson-reuters/130628/sanofi-wins-diabetes-drug-approval-japan <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>PARIS (Reuters) - French drugmaker Sanofi said it won approval from the Japanese government for its Lyxumia drug for the treatment of Type 2 diabetes in combination with basal insulin.</p> <p>Lyxumia is part of a new class of diabetes treatments called GLP-1 analogues which prompt the body to release insulin when a diabetic's blood sugar level climbs too high.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130628/sanofi-wins-diabetes-drug-approval-japan" target="_blank">read more</a></p> Diabetes Endocrine system Peptide hormones Thomson Reuters Fri, 28 Jun 2013 07:01:28 +0000 5870083 at http://www.globalpost.com Novo Nordisk raises guidance as earnings beat views http://www.globalpost.com/dispatch/news/afp/130808/novo-nordisk-raises-guidance-earnings-beat-views <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Novo Nordisk, the world's biggest producer of insulin for diabetes sufferers, posted on Thursday a rise in quarterly earnings driven by sales of diabetes drug Victoza, and raised its full-year guidance.</p> <p>Net profit in the April to June period rose 26 percent to 6.734 billion kroner (903 million euros, $1.206 billion) from the outcomea year ago, beating a Dow Jones Newswires analyst consensus of 6.5 billion kroner.</p> <p>Revenue grew 10 percent to 17.774 kroner.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130808/novo-nordisk-raises-guidance-earnings-beat-views" target="_blank">read more</a></p> Diabetes Endocrine system Novo Nordisk Peptide hormones Technology AFP Thu, 08 Aug 2013 12:47:40 +0000 5905389 at http://www.globalpost.com